U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H17N3O.C4H6O4.H2O
Molecular Weight 379.4076
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FROVATRIPTAN SUCCINATE

SMILES

O.OC(=O)CCC(O)=O.CN[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(N)=O

InChI

InChIKey=CUETXFMONOSVJA-KLQYNRQASA-N
InChI=1S/C14H17N3O.C4H6O4.H2O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13;5-3(6)1-2-4(7)8;/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18);1-2H2,(H,5,6)(H,7,8);1H2/t9-;;/m1../s1

HIDE SMILES / InChI

Molecular Formula C14H17N3O
Molecular Weight 243.3043
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H6O4
Molecular Weight 118.088
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Frovatriptan succinate (trade name Frova) is a selective 5-hydroxytryptamine1 (5-HT1B/1D) receptor subtype agonist, and is used for the treatment of migraine attacks with or without aura in adults. Frovatriptan has no significant effects on GABAA mediated channel activity and has no significant affinity for benzodiazepine binding sites. Frovatriptan is believed to act on extracerebral, intracranial arteries and to inhibit excessive dilation of these vessels in migraine. Serious but rare cardiac events have been reported in patients with risk factors predictive of coronary artery disease (CAD). These include coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.

Originator

Approval Year

PubMed

PubMed

TitleDatePubMed
Gateways to clinical trials.
2004 Apr
Evaluation of Frova, single-use intubation introducer, in a manikin. Comparison with Eschmann multiple-use introducer and Portex single-use introducer.
2004 Aug
Frovatriptan for the treatment of cluster headaches.
2004 Dec
Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine.
2004 Jul
Involvement of 5-HT1B receptors in triptan-induced contractile responses in guinea-pig isolated iliac artery.
2004 Jul
A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.
2004 Jul 27
Menstrual migraine: timing is everything.
2004 Jul 27
Gateways to clinical trials.
2004 Jun
Gateways to clinical trials.
2004 May
Frovatriptan use in migraineurs with or at high risk of coronary artery disease.
2004 May
[PercuTwist dilational tracheostomy. Prospective evaluation of 54 consecutive patients].
2004 May
Tracheostomy must be individualized!
2004 Oct
Pharmacokinetics of frovatriptan in adolescent migraineurs.
2004 Oct
Gateways to clinical trials.
2004 Sep
Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe.
2004 Sep
Regulatory and functional interactions of plant growth regulators and plant glutathione S-transferases (GSTs).
2005
The use of triptans in the management of menstrual migraine.
2005
Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials.
2005 Dec
Evidence for 5-HT2B and 5-HT7 receptor-mediated relaxation in pulmonary arteries of weaned pigs.
2005 Jan
Gateways to clinical trials.
2005 Mar
A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.
2005 Mar 8
Advanced strategies of short-term prophylaxis in menstrual migraine: state of the art and prospects.
2005 May
[Tracheotomy and tracheostomy techniques].
2005 May
The use of multiattribute decision models in evaluating triptan treatment options in migraine.
2005 Sep
Frovatriptan-induced hypomania.
2005 Summer
[Clinical use of triptans in the management of migraine].
2006
Tracheal intubation using a classic laryngeal mask airway, Frova introducer, and pediatric bronchoscope.
2006 Dec
A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.
2006 Dec 20
Shearing of a Frova Intubating Introducer by a Bronchocath double lumen tube.
2006 Feb
Clinical review: percutaneous dilatational tracheostomy.
2006 Feb
Gateways to clinical trials.
2006 Nov
Tailoring management strategies for the patient with menstrual migraine: focus on prevention and treatment.
2006 Oct
Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine.
2006 Sep
Editorial foreword.
2006 Sep
Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.
2007
Frovatriptan review.
2007 Dec
Chiral separation of Frovatriptan isomers by HPLC using amylose based chiral stationary phase.
2007 Feb 1
Latest pain relief a combination of new and old.
2007 Jan
New pain management options: drugs.
2007 Jan
In silico prediction of pregnane X receptor activators by machine learning approaches.
2007 Jan
Frovatriptan for the prevention of postdural puncture headache.
2007 Jul
Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans.
2007 Jul
Efficacy of frovatriptan.
2007 Jun
Frova intubating catheter position can be determined with aspirating oesophageal detection device.
2007 Jun
Menstrually related migraine: breaking the cycle in your clinical practice.
2007 Oct
Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine.
2007 Oct
Efficacy of frovatriptan.
2007 Sep
Acute treatment and prevention of menstrually related migraine headache: evidence-based review.
2008 Apr 22
Triptans in pregnancy.
2008 Feb
Evaluation of clinical effectiveness of the Frova single-use tracheal tube introducer.
2008 Feb
Patents

Sample Use Guides

In Vivo Use Guide
The recommended dose is a single tablet of FROVA (frovatriptan 2.5 mg) taken orally with fluids. If the headache recurs after initial relief, a second tablet may be taken, providing there is an interval of at least 2 hours between doses. The total daily dose of frovatriptan should not exceed 3 tablets (3 x 2.5 mg per day). The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Tue Oct 22 06:02:24 UTC 2019
Edited
by admin
on Tue Oct 22 06:02:24 UTC 2019
Record UNII
D28J6W18HY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FROVATRIPTAN SUCCINATE
MART.   ORANGE BOOK   USAN   USP-RS  
USAN  
Official Name English
FROVATRIPTAN SUCCINATE MONOHYDRATE
MI   WHO-DD  
Common Name English
FROVATRIPTAN SUCCINATE MONOHYDRATE [WHO-DD]
Common Name English
SB 209509-AX
Code English
SB 209509 AX
Code English
FROVA
Code English
MIGUARD
Brand Name English
FROVELAN
Brand Name English
(+)-(R)-2,3,4,9-TETRAHYDRO-3-(METHYLAMINO)-1H-CARBAZOLE-6-CARBOXAMIDE BUTANEDIOATE (1:1), MONOHYDRATE
Systematic Name English
SB-209509-AX
Code English
FROVATRIPTAN SUCCINATE [USP-RS]
Common Name English
FROVATRIPTAN SUCCINATE MONOHYDRATE [MI]
Common Name English
FROVATRIPTAN SUCCINATE [MART.]
Common Name English
VML 251
Code English
(+)-(R)-5,6,7,8-TETRAHYDRO-6-(METHYLAMINO)CARBAZOLE-3-CARBOXAMIDE SUCCINATE (1:1), MONOHYDRATE
Systematic Name English
FROVATRIPTAN SUCCINATE [USAN]
Common Name English
SB-209509AX
Code English
MIGARD
Brand Name English
FROVATRIPTAN SUCCINATE HYDRATE
Common Name English
BUTANEDIOIC ACID, COMPD. WITH (R)-2,3,4,9-TETRAHYDRO-3-(METHYLAMINO)-1H-CARBAZOLE-6-CARBOXAMIDE (1:1), MONOHYDRATE
Systematic Name English
VML-251
Code English
FROVATRIPTAN SUCCINATE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C47794
Created by admin on Tue Oct 22 06:02:24 UTC 2019 , Edited by admin on Tue Oct 22 06:02:24 UTC 2019
Code System Code Type Description
RXCUI
322249
Created by admin on Tue Oct 22 06:02:24 UTC 2019 , Edited by admin on Tue Oct 22 06:02:24 UTC 2019
PRIMARY RxNorm
MERCK INDEX
M5571
Created by admin on Tue Oct 22 06:02:24 UTC 2019 , Edited by admin on Tue Oct 22 06:02:24 UTC 2019
PRIMARY Merck Index
NCI_THESAURUS
C47544
Created by admin on Tue Oct 22 06:02:24 UTC 2019 , Edited by admin on Tue Oct 22 06:02:24 UTC 2019
PRIMARY
ChEMBL
CHEMBL1279
Created by admin on Tue Oct 22 06:02:24 UTC 2019 , Edited by admin on Tue Oct 22 06:02:24 UTC 2019
PRIMARY
CAS
158930-17-7
Created by admin on Tue Oct 22 06:02:24 UTC 2019 , Edited by admin on Tue Oct 22 06:02:24 UTC 2019
PRIMARY
WIKIPEDIA
Frovatriptan succinate
Created by admin on Tue Oct 22 06:02:24 UTC 2019 , Edited by admin on Tue Oct 22 06:02:24 UTC 2019
PRIMARY
PUBCHEM
152943
Created by admin on Tue Oct 22 06:02:24 UTC 2019 , Edited by admin on Tue Oct 22 06:02:24 UTC 2019
PRIMARY
EPA CompTox
158930-17-7
Created by admin on Tue Oct 22 06:02:24 UTC 2019 , Edited by admin on Tue Oct 22 06:02:24 UTC 2019
PRIMARY
EVMPD
SUB22174
Created by admin on Tue Oct 22 06:02:24 UTC 2019 , Edited by admin on Tue Oct 22 06:02:24 UTC 2019
PRIMARY
EVMPD
SUB127149
Created by admin on Tue Oct 22 06:02:24 UTC 2019 , Edited by admin on Tue Oct 22 06:02:24 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY